SCHEMBL7186423

SCHEMBL7186423

COC(=O)C(C(=O)c1c(C)cccc1C)c1ccccc1.O=[PH3]

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.49
KMT2A Q03164 5/20 0.49
MMP8 P22894 1/20 0.47
MEN1 O00255 3/20 0.43
PLA2G1B P04054 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ATG4B Q9Y4P1 1/20 0.43
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
ALDH1A1 P00352 2/20 0.41
GLS O94925 1/20 0.39
SRC P12931 1/20 0.39
LMNA P02545 2/20 0.39
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27484988 0.94 L3MBTL1 (0.49) L3MBTL1KMT2AMMP8MEN1PLA2G1B
SCHEMBL7185347 0.90 L3MBTL1 (0.43) L3MBTL1KMT2AMMP8MEN1PTGS1
SCHEMBL7174643 0.90 MMP8 (0.56) L3MBTL1KMT2AMMP8MEN1CA12
SCHEMBL7177876 0.88 KMT2A (0.46) L3MBTL1KMT2AMMP8MEN1NPSR1
SCHEMBL7189261 0.85 L3MBTL1 (0.47) L3MBTL1KMT2AMMP8MEN1PLA2G1B
SCHEMBL27484216 0.85 L3MBTL1 (0.43) L3MBTL1KMT2AMMP8MEN1PTGS1
SCHEMBL7181304 0.85 KMT2A (0.43) L3MBTL1KMT2AMMP8MEN1NPSR1
SCHEMBL7187383 0.84 L3MBTL1 (0.46) L3MBTL1KMT2AMMP8MEN1NPSR1
SCHEMBL7188536 0.84 KMT2A (0.47) L3MBTL1KMT2AMMP8MEN1PTGS1
SCHEMBL7189703 0.84 CA12 (0.49) KMT2AMMP8MEN1PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 L3MBTL1 302/4885KMT2A 1586/4885MMP8 4404/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 L3MBTL1 126/4885KMT2A 956/4885MMP8 4586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.